Despite the fact that they are not typically life-threatening, low-grade gliomas (LGGs) remain a significant clinical challenge in pediatric neurooncology due to co-morbidities associated with these tumors and/or their treatments, and their propensity to multiply recur. LGGs, in total the most common brain tumors arising in childhood, can often become a chronic problem requiring decades of management. The 2nd international consensus conference on pediatric low-grade gliomas held in Padua, Italy in 2016, was convened in an attempt to advance the pace of translating biological discoveries on LGGs into meaningful clinical benefit. Topics discussed included: the implications the our growing biological understanding of the genomics underlying these tumors; the assessment of the model systems available; the implications of the molecular and histopathologic differences between adult and pediatric diffuse gliomas; and steps needed to expedite targeted-therapy into late-stage clinical trials for newly diagnosed patients. Methods for the diagnostic assessment of alterations in the Ras/MAPK pathway, typical for these tumors, were also considered. While the overall tone was positive, with a consensus that progress is being and will continue to be made, the scale of the challenge presented by this complex group of tumors was also acknowledged. The conclusions and recommendations of the meeting panel are provided here as an outline of current thinking and a basis for further discussion.
Type of Publication:
Journal article published